RPL30P16

Across TCGA pan-cancer cohorts, RPL30P16 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated RPL30P16 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RPL30P16 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL30P16 expression acts as an unfavorable survival marker, although some lineages such as KIRP and OV show a favorable association.

ACC, LIHC, and KIRP are the cancer types where RPL30P16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Tertile	III,IV	0.010	0.458	<.001	63	view →
LIHC	DFS	Tertile	All	0.240	0.546	.001	36	view →
KIRP	DFS	Tertile	III,IV	1.000	0.285	.015	36	view →
ESCA	OS	Quartile	All	0.301	0.521	.004	32	view →
OV	DFS	Quartile	IV	0.507	0.253	.015	26	view →
HNSC	DFS	Tertile	IV	0.945	0.504	.006	24	view →
LUAD	DFS	Tertile	II,III,IV	0.301	0.553	.014	18	view →
SARC	OS	Tertile	All	0.317	0.745	<.001	18	view →
THYM	DFS	Tertile	All	0.426	0.883	<.001	9	view →
COAD	OS	Tertile	All	0.919	0.472	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

RPL30P16–ACC (DFS)

Open the ACC breakdown →